Cytek Biosciences, Inc.
General ticker "CTKB" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $558.0M (TTM average)
Cytek Biosciences, Inc. follows the US Stock Market performance with the rate: 47.2%.
Estimated limits based on current volatility of 2.9%: low 4.22$, high 4.48$
Factors to consider:
- Total employees count: 648 (-4.1%) as of 2024
- US accounted for 46.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Product performance and technology reliability, Geopolitical risks, Vendor dependency, Regulatory and compliance, Strategic risks and growth management
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.49$, 7.06$]
- 2026-12-31 to 2027-12-31 estimated range: [3.40$, 6.95$]
Financial Metrics affecting the CTKB estimates:
- Positive: with PPE of -11.5 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -0.73 <= 0.01
- Positive: Shareholder equity ratio, % of 74.04 > 64.29
- Positive: Investing cash flow per share per price, % of 1.58 > -0.63
- Positive: Interest expense per share per price, % of 0.07 <= 0.73
Short-term CTKB quotes
Long-term CTKB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $193.01MM | $200.45MM | $201.49MM |
| Operating Expenses | $220.86MM | $220.98MM | $241.88MM |
| Operating Income | $-27.84MM | $-20.52MM | $-40.38MM |
| Non-Operating Income | $12.14MM | $14.82MM | $10.54MM |
| Interest Expense | $2.07MM | $5.24MM | $0.47MM |
| R&D Expense | $44.15MM | $39.40MM | $36.47MM |
| Income(Loss) | $-15.71MM | $-5.70MM | $-29.84MM |
| Taxes | $-3.56MM | $0.32MM | $36.70MM |
| Profit(Loss)* | $-12.15MM | $-6.02MM | $-66.54MM |
| Stockholders Equity | $393.06MM | $395.74MM | $341.74MM |
| Inventory | $60.88MM | $43.89MM | $48.43MM |
| Assets | $494.46MM | $499.50MM | $461.54MM |
| Operating Cash Flow | $5.28MM | $25.38MM | $-4.69MM |
| Capital expenditure | $4.83MM | $3.52MM | $4.08MM |
| Investing Cash Flow | $-93.89MM | $-82.97MM | $10.12MM |
| Financing Cash Flow | $-41.81MM | $-15.82MM | $-13.43MM |
| Earnings Per Share** | $-0.09 | $-0.05 | $-0.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.